{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:35:10Z","timestamp":1791498910268,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH and CRDF Global","award":["G-202303-69963"],"award-info":[{"award-number":["G-202303-69963"]}]},{"name":"NIH and CRDF Global","award":["G-202303-69963"],"award-info":[{"award-number":["G-202303-69963"]}]},{"name":"NIH and CRDF Global","award":["G-202303-69963"],"award-info":[{"award-number":["G-202303-69963"]}]},{"name":"NIH and CRDF Global","award":["G-202303-69963"],"award-info":[{"award-number":["G-202303-69963"]}]},{"name":"NIH and CRDF Global","award":["G-202303-69963"],"award-info":[{"award-number":["G-202303-69963"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis (TB) remains a major cause of morbidity and mortality in people living with HIV (PLHIV). New TB vaccines may help reduce this burden. There is limited data on the response to new TB vaccines in PLHIV and how this may vary with levels of immunosuppression and anti-retroviral therapy (ART). The potential interaction between vaccine efficacy and ART raises questions about the optimum timing of vaccination against TB in PLHIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a simple cumulative risk model, we compared the impact of different TB vaccination strategies for PLHIV. We compared the impact of vaccinating at linkage to HIV care, to the impact of vaccinating at ART initiation. We explored how the optimum timing of vaccination depends on characteristics of the vaccine and the ART program at an individual and population level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For an individual, the optimum timing of vaccination against TB is at ART initiation unless the time to ART initiation is more than 6 months or if the reduction in vaccine efficacy when given prior to ART is small. At a population level, the proportion of PLHIV who initiate ART is a key determinate of the optimum strategy. If ART uptake is low, it would be better to vaccinate at linkage to HIV care, even if vaccine efficacy in ART na\u00efve individuals is less than 50% of efficacy in individuals on ART.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest that the optimum timing of new TB vaccination for PLHIV will depend on the relative efficacy of vaccination in ART-na\u00efve individuals vs. individuals on ART, and the uptake and timing of ART initiation. If vaccine efficacy is lower among ART-na\u00efve individuals, improvements in HIV programs may help maximize the impact of new TB vaccines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-11249-y","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:34:00Z","timestamp":1751362440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The delivery of new tuberculosis vaccines to people living with HIV \u2013 when to vaccinate?"],"prefix":"10.1186","volume":"25","author":[{"given":"Tom","family":"Sumner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomos O.","family":"Prys-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Churchyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"11249_CR1","unstructured":"World Health Organisation. Global tuberculosis report. 2024. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/363752. Accessed 2024."},{"issue":"9517","key":"11249_CR2","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","volume":"367","author":"BB Trunz","year":"2006","unstructured":"Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367(9517):1173\u201380.","journal-title":"Lancet"},{"issue":"37","key":"11249_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17370","volume":"17","author":"I Abubakar","year":"2013","unstructured":"Abubakar I, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis. Health Technol Assess. 2013;17(37):1\u2013v372.","journal-title":"Health Technol Assess"},{"key":"11249_CR4","unstructured":"Treatment Action Group. Pipeline report 2023: tuberculosis vaccines. 2023. Available from: https:\/\/www.treatmentactiongroup.org\/wp-content\/uploads\/2023\/10\/2023_pipeline_TB_vaccines_final.pdf."},{"issue":"5","key":"11249_CR5","doi-asserted-by":"publisher","first-page":"e0175215","DOI":"10.1371\/journal.pone.0175215","volume":"12","author":"CF von Reyn","year":"2017","unstructured":"von Reyn CF, et al. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: a randomized, controlled trial of DAR-901. PLoS ONE. 2017;12(5):e0175215.","journal-title":"PLoS ONE"},{"issue":"45","key":"11249_CR6","doi-asserted-by":"publisher","first-page":"e13120","DOI":"10.1097\/MD.0000000000013120","volume":"97","author":"N Kumarasamy","year":"2018","unstructured":"Kumarasamy N, et al. Long-term safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: results from a phase II randomized controlled trial. Med (Baltim). 2018;97(45):e13120.","journal-title":"Med (Baltim)"},{"issue":"3","key":"11249_CR7","first-page":"e2459","volume":"95","author":"N Kumarasamy","year":"2016","unstructured":"Kumarasamy N, et al. A randomized, controlled safety, and immunogenicity trial of the M72\/AS01 candidate tuberculosis vaccine in HIV-Positive. Indian Adults. 2016;95(3):e2459.","journal-title":"Indian Adults"},{"key":"11249_CR8","doi-asserted-by":"crossref","unstructured":"Thacher EG, et al. Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I\/II, randomized trial. AIDS. 2014;28(12):1769\u201381.","DOI":"10.1097\/QAD.0000000000000343"},{"issue":"3","key":"11249_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S2213-2600(15)00037-5","volume":"3","author":"BP Ndiaye","year":"2015","unstructured":"Ndiaye BP, et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2015;3(3):190\u2013200.","journal-title":"Lancet Respiratory Med"},{"key":"11249_CR10","doi-asserted-by":"crossref","unstructured":"von Reyn CF, et al. Prevention of tuberculosis in Bacille Calmette\u2013Gu\u00e9rin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS. 2010;24(5):675\u201385.","DOI":"10.1097\/QAD.0b013e3283350f1b"},{"issue":"11","key":"11249_CR11","doi-asserted-by":"publisher","first-page":"e791","DOI":"10.1016\/S2352-3018(22)00255-7","volume":"9","author":"MD Miner","year":"2022","unstructured":"Miner MD, et al. Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel. Lancet HIV. 2022;9(11):e791\u2013800.","journal-title":"Lancet HIV"},{"issue":"8","key":"11249_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1089\/apc.2014.0121","volume":"28","author":"NF Crum-Cianflone","year":"2014","unstructured":"Crum-Cianflone NF, Wallace MR. Vaccination in HIV-infected adults. AIDS Patient Care STDs. 2014;28(8):397\u2013410.","journal-title":"AIDS Patient Care STDs"},{"issue":"3","key":"11249_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40121-017-0166-x","volume":"6","author":"NF Crum-Cianflone","year":"2017","unstructured":"Crum-Cianflone NF, Sullivan E. Vaccinations for the HIV-infected adult: a review of the current recommendations, part I. Infect Dis Ther. 2017;6(3):303\u201331.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"11249_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/COH.0000000000000790","volume":"18","author":"I Levy","year":"2023","unstructured":"Levy I, Rahav G. The effect of HIV on COVID-19 vaccine responses. Curr Opin HIV AIDS. 2023;18(3):135\u201341.","journal-title":"Curr Opin HIV AIDS"},{"issue":"13","key":"11249_CR15","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1097\/QAD.0000000000003634","volume":"37","author":"S Mutembo","year":"2023","unstructured":"Mutembo S, et al. Measles immunity gaps among children and adolescents with HIV in Zambia despite high measles vaccination and antiretroviral therapy coverage. AIDS. 2023;37(13):2021\u20139.","journal-title":"AIDS"},{"issue":"11","key":"11249_CR16","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/infdis\/jit404","volume":"208","author":"K Rainwater-Lovett","year":"2013","unstructured":"Rainwater-Lovett K, et al. Changes in measles serostatus among HIV-infected Zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak and supplemental immunization activities. J Infect Dis. 2013;208(11):1747\u201355.","journal-title":"J Infect Dis"},{"key":"11249_CR17","doi-asserted-by":"crossref","unstructured":"Suthar A, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270.","DOI":"10.1371\/journal.pmed.1001270"},{"key":"11249_CR18","unstructured":"World Health Organisation. WHO preferred product characteristics for new tuberculosis vaccines. 2018. Available from: http:\/\/apps.who.int\/iris\/handle\/10665\/273089."},{"issue":"4","key":"11249_CR19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s10461-018-2335-7","volume":"23","author":"J Seeley","year":"2019","unstructured":"Seeley J, et al. Understanding the time needed to link to care and start ART in seven HPTN 071 (PopART) study communities in Zambia and South Africa. AIDS Behav. 2019;23(4):929\u201346.","journal-title":"AIDS Behav"},{"issue":"10","key":"11249_CR20","doi-asserted-by":"publisher","first-page":"e0286476","DOI":"10.1371\/journal.pone.0286476","volume":"18","author":"Y Tao","year":"2023","unstructured":"Tao Y, et al. Prevalence of delayed antiretroviral therapy initiation among people living with HIV: a systematic review and meta-analysis. PLoS ONE. 2023;18(10):e0286476.","journal-title":"PLoS ONE"},{"issue":"17","key":"11249_CR21","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1097\/QAD.0b013e32833ef6c4","volume":"24","author":"S Lodi","year":"2010","unstructured":"Lodi S, et al. CD4 decline in seroconverter and Seroprevalent individuals in the precombination of antiretroviral therapy era. AIDS. 2010;24(17):2697\u2013704.","journal-title":"AIDS"},{"key":"11249_CR22","doi-asserted-by":"publisher","first-page":"e4165","DOI":"10.7717\/peerj.4165","volume":"5","author":"PK Ellis","year":"2017","unstructured":"Ellis PK, Martin WJ, Dodd PJ. CD4 count and tuberculosis risk in HIV-positive adults not on ART: a systematic review and meta-analysis. PeerJ. 2017;5:e4165.","journal-title":"PeerJ"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11249-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11249-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11249-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:05:04Z","timestamp":1781604304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-11249-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11249"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11249-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"878"}}